Acquisition / mergerFiled on BSE ·
Jagsonpal Pharmaceuticals to acquire Wellness Portfolio of Group Pharmaceuticals
Jagsonpal Pharmaceuticals Ltd · Pharmaceuticals & Biotechnology
What the filing says
- Jagsonpal signed a Business Transfer Agreement on Sept 23, 2026 to acquire Group Pharma's Wellness Portfolio by slump sale.
- Initial consideration is ₹23.7 crore on closing; additional consideration up to ₹23.0 crore linked to FY 2027-28 sales, capped at ₹46.7 crore total.
- Acquisition expected to complete on or before Nov 1, 2026, subject to conditions precedent and closing terms.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Jagsonpal Pharmaceuticals Ltd
Other acquisition / merger filings this fortnight
- Acquisition / mergerMonolithisch India LtdMonolithisch India Limited investor call transcript dated September 30, 2026
- Acquisition / mergerAurobindo PharmaAurobindo Pharma subsidiary Apitoria completes acquisition of A1 Biochem Group business
- Acquisition / mergerHindustan Aeronautics LtdHindustan Aeronautics Ltd acquires 50% stake in HATSOFF Helicopter Training Pvt. Ltd
- Acquisition / mergerSahana Systems LtdSahana Defence Limited to acquire 60% stake in Siddhanta Machining Pvt Ltd
- Acquisition / mergerSahana Systems LtdSahana Defence Limited to acquire 60% stake in Siddhanta Machining Pvt Ltd
- Acquisition / mergerIndo Borax & Chemicals LtdIndo Borax acquires 64.26% stake in Kronox Lab Sciences and appoints new MD & CEO
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.